H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...
- Conditions
- Influenza
- Interventions
- Biological: A/Shanghai/02/2013 (H7N9) MIVBiological: VRC-FLUDNA071-00-VP
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 30
- Registration Number
- NCT02206464
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
- Conditions
- Gastrointestinal Inflammation Associated With CVIDCVID Enteropathy
- Interventions
- Biological: Stelara (ustekinumab)
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2020-08-24
- Target Recruit Count
- 5
- Registration Number
- NCT02199496
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
- Conditions
- Hepatitis CHIV Infections
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 46
- Registration Number
- NCT02194998
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Cincinnati Clinical Research Site, Cincinnati, Ohio, United States
Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
- Conditions
- Coccidioidomycosis
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2025-05-11
- Target Recruit Count
- 400
- Registration Number
- NCT02190266
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
- Conditions
- Liver Transplantation
- Interventions
- Biological: Anti-Thymocyte Globulin - RabbitBiological: darTreg InfusionDrug: Anti-Infective ProphylaxisProcedure: Blood drawsProcedure: Liver biopsiesProcedure: Liver transplantationProcedure: Leukapheresis
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2020-09-22
- Target Recruit Count
- 15
- Registration Number
- NCT02188719
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
- Conditions
- West Nile Virus
- Interventions
- Biological: WN/DEN4Δ30 VaccineBiological: Placebo
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2017-02-01
- Target Recruit Count
- 28
- Registration Number
- NCT02186626
- Locations
- 🇺🇸
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸Vaccine Testing Center, University of Vermont College of Medicine (UVM), Burlington, Vermont, United States
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
- Conditions
- Small Intestine TransplantLiver TransplantPTLDsHeart TransplantKidney TransplantEBV-Related PTLD
- Interventions
- Procedure: transplantDrug: Immunosuppressive Drugs
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2019-08-29
- Target Recruit Count
- 944
- Registration Number
- NCT02182986
- Locations
- 🇺🇸
Medstar Georgetown Transplant Institute, Washington, District of Columbia, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Stanford, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Drug: GSK1265744 TabletsDrug: Placebo for GSK1265744 TabletsDrug: Injectable GSK1265744Drug: Injectable Placebo for GSK1265744
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2021-10-18
- Target Recruit Count
- 199
- Registration Number
- NCT02178800
- Locations
- 🇲🇼
Malawi CRS, Lilongwe, Malawi
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇿🇦Soweto HPTN CRS, Johannesburg, Gauteng, South Africa
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
- Conditions
- Pseudomonas Infection
- Interventions
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2016-04-04
- Target Recruit Count
- 30
- Registration Number
- NCT02178254
- Locations
- 🇺🇸
Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: VRC01Biological: SC placebo for VRC01Biological: IV placebo for VRC01
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2021-10-15
- Target Recruit Count
- 88
- Registration Number
- NCT02165267
- Locations
- 🇺🇸
Columbia P&S CRS, New York, New York, United States
🇺🇸New York Blood Center CRS, New York, New York, United States
🇺🇸Penn Prevention CRS, Philadelphia, Pennsylvania, United States